2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow ANCA-associated Vasculitis: new trials by email Literature Review of ANCA-associated Vasculitis trials Research Report on ANCA-associated Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids - ANCA-associated Vasculitis | Phase 2 | Completed | Amgen | 42 | 2015-02-04 | 2025-03-13 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Vasculitis (1)
Autoimmune Diseases (2) · Cardiovascular Diseases (2) · Immune System Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Systemic Vasculitis (2) · Vascular Diseases (2) · Vasculitis (1)
Cyclophosphamide (2) · Glucocorticoids (2) · BDB001 (1) · Prednisone (1) · Rituximab (1) · avacopan (1)
Amgen (1) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (1)
Canada (1) · China (1) · United States (1)